Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252418 | 0.81 | ACP1 (0.49) | ALDH1A1ACP1SCN9AADORA2AIGF1R | |
| SCHEMBL10273110 | 0.80 | SCN9A (0.71) | KDM4EALDH1A1SCN9AADORA2A | |
| SCHEMBL17286874 | 0.80 | KDM4E (0.77) | KDM4EALDH1A1ADORA2ALMNAMAPT | |
| SCHEMBL808191 | 0.80 | KDM4E (0.77) | KDM4EALDH1A1ADORA2ALMNAMAPT | |
| SCHEMBL25257993 | 0.80 | ACP1 (0.48) | ACP1SCN9AADORA2ANUDT1 | |
| SCHEMBL808420 | 0.79 | KDM4E (0.77) | KDM4EALDH1A1ADORA2ALMNAMAPT | |
| SCHEMBL6329397 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1SCN9AADORA2ALMNA | |
| SCHEMBL4087331 | 0.78 | KDM4E (0.75) | KDM4EALDH1A1ADORA2ALMNAMAPT | |
| SCHEMBL25210790 | 0.78 | CHRNA7 (0.41) | KDM4EALDH1A1ACP1DHODHCHRNA7 | |
| Hydrochloric Acid SCHEMBL5803147 | 0.76 | KDM4E (0.72) | KDM4EALDH1A1ADORA2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | KDM4E 2897/4885ALDH1A1 829/4885ACP1 1196/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | KDM4E 2897/4885ALDH1A1 829/4885ACP1 1196/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | KDM4E 2897/4885ALDH1A1 829/4885ACP1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.